NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Organon & Co. OGN
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$6.2B
▼ 2.9% vs FY2024
EPS · FY25
$0.72
Dividend / sh · FY25
$0.34
Payout · FY25
47%
ROE · FY25
30.6%
Net margin · FY25
3.0%
Dividend coverage
2.1×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6.2B
Revenue, FY2025 · full 7-year series below
Revenue
Net income
3 cents of every revenue dollar became profit this year.
Per share
USD 0.72
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 2.1 times — the rest stayed in the company.
Profitability
30.6%
Return on equity, FY2025
ROE
Operating margin6.8%
Net margin3.0%
Return on assets1.4%
Each USD of equity produced 31 cents of profit this year.
Returned to shareholders
USD 88.0M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 88.0M
Net buybacks—
Share of profit47.1%
Consecutive raises—
USD 88.0M in dividends — 47% of the year's profit went back to shareholders.
Growth
−1.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.2%
−1.0%
Net income
−41.1%
−38.7%
EPS, diluted
−41.5%
−39.0%
Dividend / share
−32.8%
Returned to shareholders
−32.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.26B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 12.9B
total assets, end of FY2025
Total assetsUSD 12.9B
EquityUSD 752.0M
CashUSD 574.0M
Gross debtUSD 8.6B
Net debtUSD 8.1B
Current ratio1.82×
Net debt stands at 1073% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
6.2
6.4
6.3
6.2
6.3
6.5
7.8
Operating income $B
0.4
0.8
0.7
1.1
1.5
2.8
3.7
EBITDA $B
0.6
0.9
0.8
1.2
1.6
2.8
3.7
Income tax $B
0.2
−0.1
−0.3
0.2
0.2
0.5
0.4
Net income $B
0.2
0.9
1.0
0.9
1.4
2.2
3.2
EPS, diluted $
0.72
3.33
3.99
3.59
5.31
8.52
12.69
Dividend / sh $
0.34
1.12
1.12
1.12
0.56
·
·
Payout %
47
34
29
32
11
0
0
ROE %
30.6
429.9
·
·
67.9
34.5
45.7
Shares out B
0.26
0.26
0.26
0.25
0.25
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 23
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed